The experience with suramin in advanced prostate cancer
- 1 April 1995
- Vol. 75 (S7) , 1927-1934
- https://doi.org/10.1002/1097-0142(19950401)75:7+<1927::aid-cncr2820751628>3.0.co;2-a
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- SuraminCancer Treatment Reviews, 1994
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Suramin interference with transforming growth factor-β inhibition of human renal cell carcinoma in cultureJournal of Surgical Research, 1992
- Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells.Journal of Clinical Investigation, 1992
- Suramin Blockade of Insulinlike Growth Factor I-Stimulated Proliferation of Human Osteosarcoma CellsJNCI Journal of the National Cancer Institute, 1990
- Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin.Proceedings of the National Academy of Sciences, 1990
- Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2AFEBS Letters, 1989
- Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-IIIScience, 1984
- Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor virusesCancer Letters, 1979
- Suramin: With Special Reference to OnchocerciasisPublished by Elsevier ,1978